Skip to main content

Research Repository

Advanced Search

The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo

Wienke, Dirk; Davies, Gareth C.; Johnson, Damian A.; Sturge, Justin; Lambros, M. B.K.; Savage, Kay; Elsheikh, Somaia Elbauomy; Green, Andrew R.; Ellis, Ian O.; Robertson, David; Reis-Filho, Jorge S.; Isacke, Clare M.

Authors

Dirk Wienke

Gareth C. Davies

Damian A. Johnson

M. B.K. Lambros

Kay Savage

Somaia Elbauomy Elsheikh

Andrew R. Green

Ian O. Ellis

David Robertson

Jorge S. Reis-Filho

Clare M. Isacke



Abstract

Tumor cell invasion into the surrounding stroma requires increased cell motility and extensive remodeling of the extracellular matrix. Endo180 (CD280, MRC2, urokinase-type plasminogen activator receptor-associated protein) is a recycling endocytic receptor that functions in both these cellular activities by promoting cell migration and uptake of collagens for intracellular degradation. In the normal breast, Endo180 is predominantly expressed by stromal fibroblasts. The contrary observation that Endo180 is expressed on epithelial tumor cell lines that display a high invasive capacity suggested that up-regulation of this receptor may be an associated and functional component in the acquisition of a more aggressive phenotype by tumor cells in vivo. Here, we show that high levels of Endo180 are found in a subset of basal-like breast cancers and that this expression is an independent prognostic marker for shorter disease-free survival. Two potential mechanisms for Endo180 up-regulation were uncovered. First, it was shown that Endo180 can be transcriptionally up-regulated in vitro following transforming growth factor-β treatment of breast cancer cells. Second, a proportion of Endo180+ tumors were shown to have Endo180 gene copy number gains and amplifications. To investigate the functional consequence of Endo180 up-regulation, MCF7 cells transfected with Endo180 were inoculated into immunocompromised mice. Expression of wild-type Endo180, but not an internalization-defective Endo180 mutant, resulted in enhanced tumor growth together with a reduction in tumor collagen content. Together, these data argue that elevated expression of this receptor in tumor cells could have important consequences in subsets of basal-like carcinomas for which there is a current lack of effective treatment.

Citation

Wienke, D., Davies, G. C., Johnson, D. A., Sturge, J., Lambros, M. B., Savage, K., …Isacke, C. M. (2007). The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. Cancer Research, 67(21), 10230-10240. https://doi.org/10.1158/0008-5472.CAN-06-3496

Journal Article Type Article
Acceptance Date Aug 28, 2007
Online Publication Date Nov 1, 2007
Publication Date Nov 1, 2007
Deposit Date Jun 27, 2019
Journal Cancer Research
Print ISSN 0008-5472
Electronic ISSN 1538-7445
Publisher American Association for Cancer Research
Peer Reviewed Peer Reviewed
Volume 67
Issue 21
Pages 10230-10240
DOI https://doi.org/10.1158/0008-5472.CAN-06-3496
Public URL https://hull-repository.worktribe.com/output/2005776
Publisher URL http://cancerres.aacrjournals.org/content/67/21/10230